Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

IMPORTANCE: Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited. OBJECTIVE: To evaluate the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor niraparib combined with pembrolizumab in patie...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JAMA Oncol
Prif Awduron: Konstantinopoulos, Panagiotis A., Waggoner, Steven, Vidal, Gregory A., Mita, Monica, Moroney, John W., Holloway, Robert, Van Le, Linda, Sachdev, Jasgit C., Chapman-Davis, Eloise, Colon-Otero, Gerardo, Penson, Richard T., Matulonis, Ursula A., Kim, Young Bae, Moore, Kathleen N., Swisher, Elizabeth M., Färkkilä, Anniina, D’Andrea, Alan, Stringer-Reasor, Erica, Wang, Jing, Buerstatte, Nathan, Arora, Sujata, Graham, Julie R., Bobilev, Dmitri, Dezube, Bruce J., Munster, Pamela
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Medical Association 2019
Pynciau:
Original Investigation
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567832/
https://ncbi.nlm.nih.gov/pubmed/31194228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1048
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg